Jennison Associates LLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Jennison Associates LLC bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 15,291 shares of the biopharmaceutical company's stock, valued at approximately $731,000.

A number of other institutional investors have also made changes to their positions in the company. RPg Family Wealth Advisory LLC acquired a new position in Halozyme Therapeutics in the third quarter worth $1,886,000. Segall Bryant & Hamill LLC lifted its position in shares of Halozyme Therapeutics by 16.3% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company's stock worth $20,330,000 after buying an additional 49,856 shares during the last quarter. Retirement Systems of Alabama boosted its holdings in shares of Halozyme Therapeutics by 23.5% in the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company's stock valued at $22,282,000 after buying an additional 74,173 shares during the period. South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $9,812,000. Finally, Foster & Motley Inc. grew its position in shares of Halozyme Therapeutics by 118.6% during the 4th quarter. Foster & Motley Inc. now owns 23,280 shares of the biopharmaceutical company's stock valued at $1,113,000 after buying an additional 12,630 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

Shares of HALO traded up $0.24 during trading hours on Monday, reaching $57.34. 967,294 shares of the company's stock traded hands, compared to its average volume of 1,307,523. Halozyme Therapeutics, Inc. has a twelve month low of $34.36 and a twelve month high of $65.53. The business's fifty day simple moving average is $51.73 and its two-hundred day simple moving average is $54.42. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a market capitalization of $7.30 billion, a price-to-earnings ratio of 18.99, a P/E/G ratio of 0.44 and a beta of 1.25.

Analysts Set New Price Targets

A number of equities analysts have commented on HALO shares. Piper Sandler lifted their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. Wells Fargo & Company reduced their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. HC Wainwright reiterated a "buy" rating and issued a $70.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Finally, Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $60.89.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 38,611 shares of the company's stock, valued at approximately $2,173,799.30. This trade represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.